Sai Life Sciences Limited , a prominent player in the pharmaceutical industry, is now facing a fourth significant tax demand from authorities, further escalating its ongoing GST-related disputes. The latest development brings the company's total tax demands to over ₹86 crores across multiple cases.

Latest GST Penalty Order from Hyderabad

On December 30, 2025, Sai Life Sciences received a new GST order from the Additional Commissioner, Ranga Reddy GST Commissionerate, Hyderabad. The order was passed under Section 74 of the Central Goods and Services Tax Act, 2017 and Telangana Goods and Services Tax Act, 2017 read with Section 20 of the Integrated Goods and Services Tax Act, 2017.

The demand relates to alleged excess availment of Input Tax Credit and alleged differences between B2B supply with Sale/Purchase register updated on the government portal for the financial years 2018-19 to 2021-22.

Previous GST Demand from Bidar Authority

Earlier in December 2025, the company had received a GST demand order from the Deputy Commissioner of Commercial Taxes (Audit), Bidar, totaling ₹33.86 crores.

This demand pertained to alleged excess availment of Input Tax Credit in GSTR-3B compared to what was available in GSTR-2A for the financial year 2021-22.

Karnataka Tax Authority Demand

The Joint Commissioner of Commercial Taxes in Karnataka had issued an order demanding ₹36.68 crores from the company for alleged non-payment of taxes on intermediary services received from its US subsidiary.

This demand covered the period from July 2017 to March 2022, relating to services received from Sai Life Sciences Inc., USA, under the reverse charge mechanism.

Additional GST Demand

Sai Life Sciences had also received another GST demand order totaling ₹10.67 crores, including interest and penalties, for alleged excess Input Tax Credit availment and discrepancies in B2B supply records for fiscal year 2020-21.

Company's Consistent Response Strategy

Sai Life Sciences has maintained its stance of appealing all GST demand orders. Regarding the latest penalty demand, the company stated that based on its assessment, an appeal will be filed. The company remains hopeful of a favorable outcome at the appellate level and does not reasonably expect the order to have any material financial impact.

Updated Cumulative Impact

With four separate GST demands now totaling over ₹86 crores, Sai Life Sciences faces intensified regulatory scrutiny across multiple jurisdictions.

For investors and stakeholders, these developments highlight the complex nature of GST compliance, particularly regarding Input Tax Credit claims and international transactions. The outcomes of these appeals could set important precedents for the pharmaceutical sector and companies with similar operational structures.

Morgan Stanley has maintained its positive stance on Sai Life Sciences , issuing an overweight rating with a target price of ₹1,020.00 per share. This rating reflects the global investment bank's confidence in the pharmaceutical company's business fundamentals and growth prospects.

Analyst Rating Details

The overweight rating from Morgan Stanley indicates the investment bank's expectation that Sai Life Sciences may outperform relative to its pharmaceutical sector peers or broader market benchmarks. This positive assessment suggests that analysts view the company's current valuation as potentially attractive relative to its possible returns.

Market Implications

Overweight ratings are typically assigned to companies that analysts believe might offer superior risk-adjusted returns compared to their sector average. For Sai Life Sciences, this rating suggests that Morgan Stanley's research team has identified factors that could potentially drive the stock's performance above market expectations.

The ₹1,020.00 target price provides investors with a specific price objective that Morgan Stanley believes the stock could potentially achieve based on their fundamental analysis of the company's operations, market position, and growth potential within the pharmaceutical sector.